MedTrace Logo

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

NCT00100581 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-11-01

No results posted yet for this study

Summary

A significant proportion of HIV infected people in the U.S. are also infected with hepatitis C virus (HCV). The purpose of this study is to determine the effects of anti-HIV therapy on treatment of HCV with pegylated interferon alfa-2a and ribavirin (PEG/RBV).

Conditions

  • HIV Infections
  • Hepatitis C

Interventions

DRUG

Efavirenz

DRUG

Lamivudine

DRUG

Lopinavir/ritonavir

DRUG

Pegylated interferon alfa-2a

DRUG

Ribavirin

DRUG

Tenofovir disoproxil fumarate

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Barbara Gripshover, MD · University Hospitals of Cleveland, Case Western Reserve University

  • Mark S. Sulkowski, MD · Viral Hepatitis Center, Johns Hopkins University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100581 on ClinicalTrials.gov